HEPATITIS B VIRUS REACTIVATION AND PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
See full prescribing information for complete boxed warning.
- TRADE NAME: Gazyva (Genentech)
- INDICATIONS: Chronic lymphocytic leukemia (in combination with chlorambucil); follicular lymphoma (firstly with bendamustine then as monotherapy)
- CLASS: CD20-directed cytolytic monoclonal antibody, Monoclonal antibody
- HALF-LIFE: 28 days
- FDA APPROVAL DATE: 11/01/2013
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Live vaccines - PREGNANCY: Insufficient evidence to inform drug-associated risk
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of obinutuzumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
